Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: shero who wrote (3150)	6/14/1999 9:59:00 AM
From: Stephen O	Read Replies (1) \| Respond to of 3702

TECHNICLONE TREATS FIRST PATIENTS IN Pancreatic, Prostate and Liver Cancer Cotara Trial Business Editors & Medical Writers TUSTIN, Calif.--(BUSINESS WIRE)--June 14, 1999-- -Clinical Study Could Significantly Reduce US Approval Timeline- Techniclone Corporation (NASDAQ:TCLN) a developer of leading-edge unique therapeutics for the advanced treatment of cancer, today announced that it has begun treating its first two prostate cancer patients under its Cotara(TM) Phase I/II trial for the treatment of pancreatic, prostate and liver cancers. The Company expects that the results from this study, if accepted by the FDA, would replace the need for a U.S. Phase I clinical trial study, therefore potentially reducing the U.S. approval timeline and possibly leading to faster commercialization. Techniclone anticipates that these studies will also provide valuable insight into Cotara's(TM) ability to treat a variety of solid tumors and will make the design of future studies more efficient. As previously announced, Techniclone received an unrestricted grant to fund a portion of this trial from a New York Stock Exchange (NYSE) multinational pharmaceutical company. Conducted at the Salvador Zubrian National Nutrition Institute in Mexico City under the direction of Dr. Gabriela Cesarman of the Department of Hematology and Oncology, the trial will include approximately eighteen patients with advanced prostate, pancreatic and liver cancers and will explore the benefits of alternative delivery procedures (which include intratumoral and intravenous injection). Larry O. Bymaster, President and CEO of Techniclone, stated, "Each year over 1.3 million Americans are diagnosed with various forms of solid tumor cancer, more than one third of which result in death. While some inroads have been made in various individual areas of cancer research, the search for a universal therapy continues and we believe that the various studies presently being conducted on our Cotara(TM) therapy have the potential to provide an important milestone in that effort." In addition to the Mexico City trial, Cotara(TM) which binds to dead/decaying cells found in the core of solid tumors is presently in Phase II clinical trials in the U.S. for malignant glioma (brain cancer). Company Overview: Techniclone Corporation is a biopharmaceutical company focused on the development, commercializing and licensing of unique technologies for the treatment of cancer, primarily based on its "collateral targeting technologies." These technologies therapeutically target cell structure and cell types, rather than surface cancer cells, as a means to attack solid tumors, without causing damage to surrounding healthy tissue. In addition to Cotara(TM), the Company has a direct tumor targeting agent called Oncolym(R) for the treatment of advanced non-Hodgkin's B-cell Lymphoma, that is currently undergoing Phase II/III human testing. Techniclone recently entered into a worldwide Licensing Agreement for Oncolym(R) with Schering AG, Germany. Two other collateral targeting agents, Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA) are in pre-clinical stages of development. VEAs are monoclonal antibodies that increase tumor blood vessel permeation for enhanced uptake of chemotherapeutic agents versus normal tissues, while VTAs are agents that block the flow of oxygen/nutrients to a solid tumor's vascular network, causing clotting and necrosis. VTAs also can deliver a wide variety of therapeutic agents to a solid tumor, including therapeutic agents, biologic agents, toxins and radioisotopes. Additional information on the Company and its products can be found at www.techniclone.com. Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the Company's expectations as a result of risk factors discussed in Techniclone's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's report on Form 10Q for the quarter ended January 31, 1999 and Form 10K for the year ended April 30, 1998. --30--flb/ny* CONTACT: Investor Relations: Cynthia DeMonte 212/420-0088 or Media Relations: Clint Cantwell/Rubenstein PR 212/843-8051